NEW YORK (GenomeWeb) – Diagnostics developer HealthTell announced today that it has completed a $26 million Series B financing round led by Third Point Ventures.

The company, which also raised $14 million in a previous Series A round, plans to use the proceeds to commercialize panels for tests for autoimmune diseases, such as lupus.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.